Lv1
54 积分 2025-03-12 加入
PTPRT loss enhances anti–PD-1 therapy efficacy by regulation of STING pathway in non–small cell lung cancer
4个月前
已完结
CheckMate 9LA: broadening treatment options for patients with non-small-cell lung cancer
4个月前
已完结
Resistance to PD-1/PD-L1 immune checkpoint blockade in advanced non-small cell lung cancer
4个月前
已完结
The multiple roles of LDH in cancer
5个月前
已完结
Anti-angiogenesis revisited: reshaping the treatment landscape of advanced non-small cell lung cancer
5个月前
已完结
Prognostic scores including peripheral blood-derived inflammatory indices in patients with advanced non-small-cell lung cancer treated with immune checkpoint inhibitors
5个月前
已完结
Low-dose anlotinib confers improved survival in combination with immune checkpoint inhibitor in advanced non-small cell lung cancer patients
5个月前
已完结
Anti-Angiogenic Agents Combined with Immunotherapy for Advanced Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis
5个月前
已完结
The significance of inflammatory markers in prognosticating the effectiveness and safety of immunotherapy in conjunction with chemotherapy during the primary intervention of advanced non-small cell lung carcinoma
6个月前
已完结
Telisotuzumab Vedotin: First Approval
6个月前
已完结
皖公网安备34019202002308
